Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

The aim of the study was to evaluate the effect of prebiopsy administration of desmopressin acetate versus placebo in the incidence of postbiopsy bleeding complications.

Why It Was Studied

Single-center design of the study.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vasopressin group a baseline to be compared against.

Double-blind randomized controlled clinical trial.

What Was Measured

Topics PubMed links to this paper include Biopsy, Deamino Arginine Vasopressin, Hemorrhage, Hemostatics, Incidence, Kidney and Kidney Diseases.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2011 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.